Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 23Cr 27Cr 25Cr 21Cr 39Cr 2.56TCr 40Cr 272.24Cr 108.51Cr 1.37TCr 102.38Cr 100.2Cr 4.36TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 25Cr 30Cr 27Cr 22Cr 42Cr 2.79TCr 43Cr 296.57Cr 118.2Cr 1.49TCr 111.53Cr 109.16Cr 4.75TCr EV / Sales 2026 *
2.61x
EV / Sales 2027 * 2.08x
Free-Float
84.95%
Yield 2026 *
-
Yield 2027 * -
1 day+2.90%
1 week+4.23%
Current month-0.26%
1 month+4.80%
3 months-3.78%
6 months-11.68%
Current year+21.27%
1 week 14.32
Extreme 14.32
15.38
1 month 13.42
Extreme 13.42
16.04
Current year 11.7
Extreme 11.7
18.84
1 year 10.12
Extreme 10.12
18.84
3 years 7.21
Extreme 7.21
18.84
5 years 5
Extreme 5
20.3
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 15/07/2026
Director of Finance/CFO 51 24/02/2025
Chief Operating Officer 55 01/09/2022
Director TitleAgeSince
Chairman 64 30/06/2022
Director/Board Member 58 04/04/2017
Director/Board Member 47 27/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
22/01/24 Buy 30,228 0.2396%
06/07/23 Buy 2,000 0.0016%
11/01/22 Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
+2.96%+4.23%+42.27%+52.50% 27Cr
+0.89%+6.04%+42.19%+136.19% 1,28000Cr
+1.25%+4.19%+45.96%+92.20% 68TCr
+0.62%+2.94%+27.21%+114.01% 52TCr
+1.16%+3.83%+40.05%+70.35% 39TCr
+0.61%+0.65%+61.72%+44.33% 36TCr
+1.12%+0.09%+28.21%+58.64% 30TCr
+0.27%-0.60%+3.25%+36.20% 29TCr
+0.58%+2.31%+40.04%+76.58% 25TCr
+0.41%+1.78%+38.21%+127.61% 21TCr
Average +0.97%-0.70%+36.91%+80.86% 43TCr
Weighted average by Cap. +0.84%+0.20%+38.51%+96.70%

Financials

2026 *2027 *
Net sales 9.47Cr 11Cr 10Cr 8.56Cr 16Cr 1.07TCr 17Cr 113.49Cr 45Cr 571.27Cr 43Cr 42Cr 1.82TCr 12Cr 14Cr 13Cr 10Cr 20Cr 1.3TCr 20Cr 138.48Cr 55Cr 697.04Cr 52Cr 51Cr 2.22TCr
Net income - -
Net Debt 2.03Cr 2.44Cr 2.2Cr 1.84Cr 3.47Cr 228.65Cr 3.56Cr 24Cr 9.7Cr 122.46Cr 9.15Cr 8.95Cr 389.7Cr 1.34Cr 1.61Cr 1.45Cr 1.21Cr 2.29Cr 150.93Cr 2.35Cr 16Cr 6.4Cr 81Cr 6.04Cr 5.91Cr 257.24Cr
Projected Income Statement - Annual - Santhera Pharmaceuticals Holding AG
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
12/26/12 CHF 15.28 +2.96% 63,084
11/26/11 CHF 14.84 -0.67% 58,579
10/26/10 CHF 14.94 -1.71% 21,698
09/26/09 CHF 15.20 +1.88% 43,695
06/26/06 CHF 14.92 +1.77% 49,689
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Santhera Pharmaceuticals Holding AG
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.84CHF
Average target price
27.50CHF
Spread / Average Target
+85.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Santhera Pharmaceuticals Holding AG
  1. Stock Market
  2. Stocks
  3. SANN Stock